Slide 1: SPEARHEAD and beyond: Sustaining the fight against antimicrobial resistance
SPEARHEAD and beyond: Sustaining the fight against antimicrobial resistance 17.11.2025 Funded by Innosuisse
Slide 2: Welcome words
09.30-09.40 Welcome words Christoph Nabholz, SwissRe, Saara Malkamäki, University of Basel
Slide 3: AMR attributable/associated mortality
AMR attributable/associated mortality 2050 2021 8.2m 4.7m associated deaths associated deaths 1.1m 1.9m attributable attributable deaths deaths Source: VizHub - MICROBE (healthdata.org), accessed November 2025 3
Slide 4: Swiss Re Life & Health Reinsurance market overview
Swiss Re Life & Health Reinsurance market overview Geographically diversified premium split Portfolio composition % of net earned premium by geography 2024 % of net earned premium by segment 2024 Mortality 58% Americas Longevity 14% 51% Critical illness 11% EMEA 30% Disability 11% Asia Medical 6% 19
Slide 5: WHO and SPEARHEAD LinkedIn links
WHO: https://www.who.int/campaigns/w orld-amr-awareness-week/2025 SPEARHEAD’s LinkedIn page: linkedin.com/company/spearhea d-amr
Slide 6: Voice of Patients
09:40-09:45 Voice of Patients Ginevra Terenghi, University of Applied Sciences and Arts of Southern Switzerland
Slide 7: Voice of Patients
Voice of Patients T decided to because every time It happened doctor started Tstarted feeling Tam old , based in _I was feeling I've been told by that I was suffering from for to me that Ultimately, the cure .Inoticed So, I tried Now “4e,, Spearhead Innovating against AVR
Slide 8: Voice of Patients
. . “4... Spearhead Voice of Patients 8 een [ decided to consult with my doctor (“) because of a UTI . I was feeling discomfort and pain every time | was seeing and sitting. I've been told by the doctor (“) that | was suffering from a urinary infection. It already happened 2 weeks before. The doctor
Slide 9: Voice of Patients
Spearhead Innevating agzinst AMR Voice of Patients Giagnosis) (symptoms) (treatment) (follow-up) (demographics) 000 Ba ewieccctnion-aoeges x 4 : € > @ % docs.google.com/spreadsheets/d/1kiM/1AicL4Or0dP9YUSS7sI3aVYoFLks-O24hpSZAGl/edit?gid=192e45065Hgid-1926.. QA xe OOH G0H GO HEC vekco Sus) Cane Corm
Slide 10: Voice of Patients
Voice of Patients For months I lived with stomach pain and constant bladder infections. Every meal made me anxious because I knew it would hurt again. Doctors kept changing antibiotics and supplements, but nothing really changed. I started realising how much the stress in my life was affecting my bo
Slide 11: Voice of Patients
Voice of Patients While travelling, I started feeling pain when peeing and constant tiredness. I didn’t know where to go or who to ask for help, everything felt unfamiliar. The local doctor didn’t speak much English and gave me antibiotics right away. They helped at first, but I soon felt nauseous a
Slide 12: Voice of Patients
Voice of Patients My doctor said I had another urinary infection and gave me antibiotics. At first they helped, but soon the same symptoms returned. I kept changing medicines and became resistant to one of them. Now I get these infections more often and try to manage them better. It’s tiring but at
Slide 13: Voice of Patients
Voice of Patients I ended up in the hospital because the pain in my belly was unbearable. They said it was just a urinary infection and gave me antibiotics. I got weaker every day, my throat and skin started to burn. A healer finally told me to see a urologist, and they found a stone. After the surg
Slide 14: Voice of Patients
Voice of Patients [P112] [P32] [P21] [P16] 14
Slide 15: Keynote: Reducing the 80% - a community healthcare perspective on AMR
09:45-10:10 Keynote: Reducing the 80% - a community healthcare perspective on AMR Gail Hayward, Nuffield College, Oxford University
Slide 16: Reducing the 80% - a community healthcare perspective on AMR
Reducing the 80% - a community healthcare perspective on AMR Professor Gail Hayward Director, NIHR Community Healthcare Healthtech Research Centre Nuffield Dept of Primary Care Health Sciences, University of Oxford
Slide 17: Antimicrobial stewardship challenges in community care
Antimicrobial stewardship challenges in community care • Frontline gatekeepers ~ 90% of UK NHS contacts • Approximately 80% of all antibiotic prescriptions – at least 20% inappropriate • Antibiotic prescriptions in community settings drive resistant infections and hospitalisations
Slide 18: Acute Respiratory Tract Infections
Acute Respiratory Tract Infections • Acute Respiratory Infections (ARIs) such as cough and sore throat account for 46% of antibiotics prescribed in primary care • Most infections are self-limiting, including bacterial infections • Randomised Trials have shown that antibiotics offer no benefit over p
Slide 19: ARI presentations across European countries
• ARI presentations across European countries do not differ significantly, however antibiotic prescribing does.
Slide 20: Antibiotic prescribing is a behaviour
Antibiotic prescribing is a behaviour • Multiple influences on clinician antibiotic prescribing behaviour. • To change behaviour you need to target these influences Patient history & physical examination General impression & gut feeling Mutual trust and confidence with the patient (Perceived) Patien
Slide 21: Behaviour change interventions
Behaviour change interventions • Audit and feedback • Enhanced communication skills training for clinicians • Reminders/computer pop-ups • Patient information leaflets • Educational meetings/outreach visits for clinicians • Diagnostics • Shared decision making aids • Financial incentives • Delayed p
Slide 22: Diagnostics may not change behaviour in the way we might hope
Diagnostics may not change behaviour in the way we might hope… Definitely don’t Might need Definitely need need antibiotics antibiotics antibiotics • Offer clinicians additional information to support the riskier decision Not to prescribe where a patient is in the grey zone Definitely don’t Might ne
Slide 23: However in research..
However in research.. • Observed to • help reassure clinicians and patients about NOT prescribing when that was already the clinical decision, • prompt clinicians to prescribe when they might not have without the test result Definitely don’t Might need Definitely need need antibiotics antibiotics an
Slide 24: Point-of-care testing and antibiotics prescribing in Denmark
Christensen LD, Vestergaard CH, Keizer E, Bech BH, Bro F, Christensen MB, Huibers L. Point-of-care testing and antibiotics prescribing in out-of-hours general practice: a register-based study in Denmark. BMC Prim Care. 2024 Jan 23;25(1):31.
Slide 25: Opportunities – Acute Respiratory Tract infection
Opportunities – Acute Respiratory Tract infection • Contexts where most patients currently get antibiotics • COPD • Epidemic GAS / Pharmacy First • Positive identification of viral respiratory pathogens
Slide 26: PACE study
PACE study What was learnt about the CRP test? with COPD took part from In the 4 weeks following initial consultation: Three quarters Just over half of patients of patients took antibiotics took antibiotics ‘7 in antibiotic use when using the test NIHR | coimuniyheatincare
Slide 27: Epidemic infections
Epidemic infections Pharmacy led sore throat test and treat service • Of 27 441 STTT consultations in a year, 9308 (33.9%) occurred during December 2022. • Following announcement of increased iGAS incidents, • increase of 1700 consultations • decrease in supply rate of 13.9 antibiotics per 100 RADT
Slide 28: Positive identification of viral respiratory pathogens
Positive identification of viral respiratory pathogens RAPID-Dx - RCT comparing viral diagnostic panel guided care to usual care for RTI now complete and pending publication… Combining different types of tests? PRUDENCE RCT comparing combined biomarker and pathogen POCT guided care to usual care now
Slide 29: Future approaches to ARI
Future approaches to ARI Prognostics – when are antibiotics needed to avoid complications and hospitalisation from bacterial infection, and when will the body resolve this on its own? Better prevention / early treatment to avoid the need for healthcare contact ‘the best way to avoid an antibiotic is
Slide 30: Opportunities: Urinary Tract Infection
Opportunities: Urinary Tract Infection • 6 million antibiotics prescribed for UTI in the UK annually • Multidrug resistance is rising and has implications wider than ‘simple’ UTI – urosepsis, pyelonephritis • Costs of UTI management £604 million in 2023-24 in the UK
Slide 31: How do GPs currently decide who needs antibiotics?
How do GPs currently decide who needs antibiotics? • Diagnostic Algorithms • Dipstick • Culture
Slide 32: How well do UK guidelines predict UTI?
How well do UK guidelines predict UTI? We asked this question using data from 1062 women aged 18+ with suspected uncomplicated UTI
Slide 33: SIGN and UKHSA guidance results
• SIGN guidance • hardly any women with a negative urine culture received antibiotics, • BUT only 13.7% of women with a positive culture received antibiotics • UKHSA guidance • 81% of all women with positive culture received antibiotics, • BUT 61% of all women with negative culture received antibiot
Slide 34: Dipstick
Dipstick • Qualitative = interpretation can vary • Multiple variables = unclear how to interpret • Diagnostic performance poor in primary care • Women with negative dipsticks randomised to antibiotics have more rapid symptom resolution
Slide 35: Urine Culture – an imperfect reference standard diagnostic
Urine Culture – an imperfect reference standard diagnostic • Long delay to receiving the result: Patients often don’t receive the result until antibiotic course complete • 30% contaminated = clinically useless • Cannot distinguish between infection and asymptomatic bacterial carriage • May miss pote
Slide 36: UTI Point of Care Tests
UTI Point of Care Tests • Information available rapidly enough to guide prescribing – a point of prescription diagnostic • Possibly….reduced risk of contamination because of immediate testing
Slide 37: How could point of care tests help?
How could point of care tests help? • Bacterial presence and identification – by genetic markers or by imaging • Avoiding unnecessary antibiotics • Ensuring clinician considers alternative diagnoses (endometriosis, STIs, cancer)
Slide 38: How could point of care tests help?
How could point of care tests help? Antibiotic susceptiblity • Ensures the antibiotic choice is guided by phenotypic susceptibility rather than guesswork based on regional data • Supports usage of narrower spectrum antibiotics with less side effects which cannot be prescribed empirically
Slide 39: Sysmex-Astrego PA-100 AST
Sysmex-Astrego PA-100 AST • Provides results in 30 - 40 min • Estimates bacterial load in urine (CFU) • Conducts an Antibiotic Susceptibility Test (AST)
Slide 40: Host response
Host response • Could overcome the challenge of distinguishing asymptomatic carriage from infection • particularly relevant for patients who do not experience or communicate typical symptoms • We found: 66 biomarkers have been tested in 37 studies, no convincing evidence to date • DISCO UTI study
Slide 41: Why aren't these tests already guiding care?
Why aren’t these tests already guiding care?
Slide 42: Platform for UTI diagnostic evaluation
NIHR | csanusiyfeirnce plaTform fOr Uti diagnostiC evaluation
Slide 43: Platform diagnostic accuracy study
Platform diagnostic accuracy study • Women can produce lots of urine.. • Efficient: Allows multiple diagnostics to be evaluated simultaneously with sample sizes appropriate for the performance and diagnostic capabilities • Flexible: • Provides definitive diagnostic performance information for diagno
Slide 44: TOUCAN
TOUCAN • Adult Women presenting with suspected uncomplicated UTI • Up to 3 point of care diagnostics performed on the sample • Enhanced reference standard testing in a central study laboratory • Currently: >1000 women recruited, 4 tests evaluated and pending publication, 3 tests joining the platform
Slide 45: Towards a future of diagnostic enhanced primary care stewardship
Towards a future of diagnostic enhanced primary care stewardship • Better evidence, ideally generated in efficient platform studies • Economic arguments which take into account • Budget silos • A future without antibiotics • Laboratory / clinical engineering / primary care partnerships to ensure saf
Slide 46: Ideas / questions / want to collaborate?
Ideas / questions / want to collaborate? • Gail.hayward@phc.ox.ac.uk
Slide 47: Keynote - Current and future policies in AMR
10:10-10:35 Keynote - Current and future policies in AMR Barbara Schedler Fischer, Federal Office of Public Health (FOPH), Switzerland's Ambassador for Global Health
Slide 48: SPEARHEAD project: Summary and Results
11:30-12:10 SPEARHEAD project: Summary and Results Saara Malkamäki, Hailey Kim, University of Basel, Christoph Meier, University Hospital Basel (USB), Lina Aerts, UKBB, Daniele Malpetti, SUPSI Dalle Molle Institute for Artificial Intelligence (IDSIA) Gilbert Greub & Alexandre Delfino, Centre Hospita
Slide 49: Why SPEARHEAD?
Why SPEARHEAD? To tackle silent pandemic of antimicrobial resistance with research-based digital solutions & patient-centric approach, addressing stewardship and prevention
Slide 50: A unique Swiss-wide partnership between research & industry
A unique Swiss-wide partnership between research & industry Supported by:
Slide 51: Our goals
OUR GOALS Spearhead will leverage big data, machine learning, rapid diagnostics and digital media to help doctors make quick and effective treatment choices, and patients and citizens to become more confident in the usage of antibiotics. THE PROJECT HAS FIVE MAIN GOALS 2 Utilise rapid diagnostics to
Slide 52: Holistic approach to tackle AMR
Holistic approach to tackle AMR Prevention Stewardship SP1 Real-time Monitoring System SP3 Federated Data Civic Engagement Network Risk Prediction Model SP2 SP4 Advanced Rapid Diagnostic Test Health-economic Impact
Slide 53: SP1: Real-Time Monitoring System: The Problem
SP1: Real-Time Monitoring System: The Problem -inappropriate indication -inappropriate spectrum -inappropriate dosage -inappropriate duration -intravenous to oral switch possible 53
Slide 54: SP1: Real-Time Monitoring System: The Innovation → DrugAlert
SP1: Real-Time Monitoring System: The Innovation → DrugAlert Backend Frontend 54
Slide 55: SP1: DrugAlert: Key Results
SP1: DrugAlert: Key Results Notification as Inhouse-Medical Device ➞ 55
Slide 56: SP1: DrugAlert: what's next
SP1: DrugAlert: what’s next - Inhouse - Expansion to other medication and clinics - Microbiological testing as a mandatory procedure for the approval of an antibiotic therapy? - Expansion to other institutions outside our hospital? ➞ - Certification as Medical Device is needed - IT Partner? - Start-
Slide 57: SP2b—NANOMUR
SP2b—NANOMUR Rapid Antibiotic Susceptibility Testing for Urinary Tract Infections Using Innovative Nanomotion Technology Alexandre Delfino, MD-PhD candidate Prof. Gilbert Greub 57
Slide 58: Presentation in pair—Role play
Presentation in pair—Role play: Alexandre Delfino as microbiologist Gilbert Greub as physician 58
Slide 59: Background—Antibiotic Susceptibility Testing (AST)
Background—Antibiotic Susceptibility Testing (AST) 59
Slide 60: Background—Antibiotic Susceptibility Testing (AST)
Background—Antibiotic Susceptibility Testing (AST) 60
Slide 61: Background—Nanomotion
Background—Nanomotion Rectangularcantilever at microscopy 61
Slide 62: Background—Nanomotion
Background—Nanomotion Detector Light source 62
Slide 63: Results—Time-to-result
chy Results—Time-to-result 4 Spearhead Innevating agzinst AMR 10 iance [V“2V“2) 5 — Blank — Medium phase —— Medium with drug phase ¢ Blank phase = medium only (LB %) * Bacphase =medium + bacteria ¢ Drugphase = medium + bacteria + antibiotic 63
Slide 64: Results—Time-to-result
chy Results—Time-to-result | Total time-to-result =~ 4.5 hours |
Slide 65: Nature Communications article on nanomotion AST
nature communications fo} Article https://doi.org/10.1038/s41467-024-46213-y Accurate and rapid antibiotic susceptibility testing using a machine learning-assisted nanomotion technology platform Received: 1 June 2023 Alexander Sturm ®©' °, Grzegorz Jézwiak', Marta Pla Verge ®', Laura Munch', Gino Ca
Slide 66: Results—Performance
€. Ov Results—Performance > Trained on 81 urine samples (10 R) > 3-fold cross-validation protitter PhD ettlent Oliver Y. Chen Duy-Cat Can Precision | Sensitivity F1 score Accuracy | Specificity Random Forest 95.83 97.18 96.50 93.83 70.00 SVM 89.87 100.00 94.67 90.12 20.00 Logistic Regression 93.33 9
Slide 67: Conclusions
® Spearhead Conclusions * Nanomotion is > 30 hours faster ¢ Performance is good > Depends on the machine-learning model 67
Slide 68: Conclusions
4 Spearhead PH Er, Speatnead Conclusions * Nanomotion is > 30 hours faster ¢ Performance is good > Depends on the machine-learning model Future work > Nanomotion experiment at 37°C > Reducing recording time to 2 hours 68
Slide 69: Acknowledgments
4 Spearhead PH Ey, Speathead Acknowledgments Prof. Greub’s lab Prof. Chen’s group Alexandre Delfino Dr. Amanda Luraschi Dr. Maria Georgieva Solange Matos Professor PhD student Oliver Y. Chen Duy-Cat Can Sébastien Aeby a i (© Resistell Dr. Alex Sturm Dr. Danuta Cichocka 69
Slide 70: Thank you for your attention!
Thank you for your attention! Les bactéries font de la résistance C. Aubry et G. Greub EPFL Press, 2026 70
Slide 71: SP2a - Risk prediction
SP2a - Risk prediction Predicting antibiotic resistance risk in urinary tract infections using machine learning to support smarter empirical prescribing in hospitalised children and adults. Daniele Malpetti and Lina Aerts 71
Slide 72: Clinical challenges in empiric antibiotic prescriptions for patients with UTI
Clinical challenges in empiric antibiotic prescriptions for patients with UTI Rapid decisions without susceptibility data AB prescription needs to be AB prescription based on the personalized and take into antibiotic susceptibilities of account the medical history of the infecting pathogen the patie
Slide 73: SP2: Risk prediction model from clinical data
SP2: Risk prediction model from clinical data Can antibiotic resistance be effectively predicted Evidence in our data (USB) based solely on patient history and routinely performed laboratory tests? Evidence from literature Predictive performance is promising. But key questions remain: are there diff
Slide 74: SP2: Risk prediction model from clinical data
SP2: Risk prediction model from clinical data In adults, past resistance Across adults, being male Pregnancy status also emerges as the strongest consistently appears as a emerges as a relevant predictor of future higher-risk factor than predictor contributing resistance. being female. additional ri
Slide 75: SP2: Risk prediction model from clinical data
SP2: Risk prediction model from clinical data A web interface to support clinicians with predicted resistance. Use of a limited number of widely available clinical variables. Currently under development. 75
Slide 76: Behind The Scenes
Behind The Scenes
Slide 77: From vision to practice – Building bridges for ethical AMR stewardship
From vision to practice – Building bridges for ethical AMR stewardship Equity Diversity & Fairness Trustfulness Inclusion Fair representation Multiple voices Privacy protected Trust and across regions & and perspectives by design communication communities shape the system between the people who buil
Slide 78: Stakeholder journey
Stakeholder journey Federated Learning Technical Stakeholder Regulatory Barriers Basel UTI Cohort Vision Breakthrough Collaboration Equity, FL framework IT teams, data No general Feasibility diversity, built & scientists, consent, legal successfully inclusion; published; lawyers, ethics uncertainty,
Slide 79: Conclusion
Conclusion Our models perform well across diverse patient groups and show potential to support clinical decision-making and guide empiric antibiotic prescribing. However, responsible innovation requires more than strong algorithms. Ethical AMR stewardship relies on three things: data governance, col
Slide 80: On behalf of the team, Thank you for your attention!
On behalf of the team, Thank you for your attention! Julia Bielicki, Prof. MD-PhD Laura Azzimonti, PhD Angela Huttner, Prof. MD-PhD Paediatric Infectious Diseases, Senior Researcher and Lecturer, Infectious Diseases Division and UKBB IDSIA, USI/SUPSI director of the Clinical Investigation Unit, HUG
Slide 81: SP3: Citizen Engagement and Education
SP3: Citizen Engagement and Education The on-boarding of the population is a fundamental strategy to tackle AMR and pandemics challenges. Informing, educating and creating awareness are key actions that are combined to implement effective AMR plans with a focus on the societal impact. 81
Slide 82: Subproject 3: Societal Adoption and Awareness
Subproject 3: Societal Adoption and Awareness The on-boarding of the population is a fundamental strategy to tackle AMR and pandemics challenges. Informing, educating and creating awareness are key actions that are combined to implement effective AMR plans with a focus on the societal impact. (The c
Slide 83: Subproject 3: Societal Adoption and Engagement
Subproject 3: Societal Adoption and Engagement If engaging the population is an “emergency” in public health, is one-way science communication—from experts to citizens—treally the solution? Drawing from bottom-up and transdisciplinary practices, we explored how to innovate public engagement by imple
Slide 84: Subproject 3: Societal Adoption and Engagement - MAKEAWARE!
Subproject 3: Societal Adoption and Engagement - MAKEAWARE! Data pills oa@anit WOrkatges @) to raisef yireness in| <> antibiow’ gonsumptigy and antimicls Soial¢ esis ce
Slide 85: Subproject 3: Societal Adoption and Engagement - Dataviz
Subproject 3: Societal Adoption and Engagement - Dataviz HOME WORKSHOPS STORY-COLLECTIONTOOL DATABOOK CHATBOT PUBLICATIONS Number of resistant bacteria observed by country in 2020. In 2020, Switzerland (¢) has registered 158 antimicrobial resistant bacteria out of 11958. samples taken. Data source:
Slide 86: Subproject 3: Societal Adoption and Engagement
Subproject 3: Societal Adoption and Engagement Designing methods and tools for fostering a citizen data co-creation approach on AMR and antibiotic consumption to raise awareness and to test and validate a model of people-led innovation and research in digital (public) healthcare. (From education to
Slide 87: Subproject 3: Transdisciplinary Workshops Protocols
Subproject 3: Societal Adoption and Engagement - Transdisciplinary Workshops Protocols HOME WORKSHOPS STORY-COLLECTIONTOOL DKTABOOK CHATEOT PUBLICATIONS Powered by SPEARHEAD Design perspectives on digital healthcare 1( DiPLab - Digital Petri Laboratory OpenHealth datathon MAKEAWARE! toa event Intera
Slide 88: Subproject 3: Transdisciplinary Workshops Protocols
Subproject 3: Societal Adoption and Engagement - Transdisciplinary Workshops Protocols Designing future ; patient-led conversations OpenHealth datathon 2st June 2024 14.00-21.00 Novartis Pavillon St. Johanns-Hafen-Weg 5 4056 Basel spearhead-project.ch Doctors, nurses, designers, technologists, patie
Slide 89: Subproject 3: Societal Adoption and Engagement - Databook
Subproject 3: Societal Adoption and Engagement - Databook HOME WORKSHOPS STORY-COLLECTIONTOOL DATABOOK CHATBOT PUBLICATIONS. Powered by SPEARHEAD #108 #107 I decided to fare molte visite e prendere diversi antibiotici e integratori - because avevo sempre mal di stomaco e ogni due settimane mi veniva
Slide 90: Subproject 3: Societal Adoption and Engagement - Chatbot
Subproject 3: Societal Adoption and Engagement - Chatbot HOME WORKSHOPS STORY-COLLECTIONTOOL DATABOOK CHATBOT PUBLICATIONS Powered by SPEARHEAD Do you have questions about MAKEAWARE!? Ask the chatbot, created from the project’s own sources and documentation, to get clear explanations of its topics,
Slide 91: Subproject 3: Social Media Campaign
Subproject 3: Societal Adoption and Engagement - Social Media Campaign (DEFINITION OF RECURRENT uTIS) S reach 218,188 views 428,399 clicks 4339 RECURRENT UTIS ARE COMMON IN WOMEN, DEFINED AS TWO OR MORE INFECTIONS IN SIX MONTHS OR THREE OR MORE IN A YEAR. Recurrent UTIs & Susceptibility
Slide 92: Subproject 3: outcomes and learnings
Subproject 3: Societal Adoption and Engagement - outcomes and learnings If the on-boarding of the population is an emergency in Public Health, these are some of the key learnings that lead to solutions: - Validated methods of citizen data co-creation beyond traditional data collection that challenge
Slide 93: Subproject 3: outcomes and learnings
Subproject 3: Societal Adoption and Engagement - outcomes and learnings As an innovation outcome, Subproject 3 delivered the architecture of a digital infrastructure to enable the implementation of participatory research in public health: an experimental local AI inrastructure for protected and ethi
Slide 94: Subproject 3: Societal Adoption and Engagement - People
Subproject 3: Societal Adoption and Engagement - People a NY Serena Cangiano Gi Terenghi Antonella Autuori Matteo Subet SUPSI Design Institute SUPSI Design nstitute SUPSI Design Institute SUPSI Design Institute Research lea PhD student, project coordinator PhD student PhD student Zoe Romano Pamela P
Slide 95: SP4: Health economics & HTA
SP4: Health economics & HTA 95
Slide 96: SP4: Antimicrobial Resistance in Switzerland: economic consequences
SP4: Antimicrobial Resistance in Switzerland: a report with focus on economic consequences • Overall antibiotic use is comparatively low, but regional variation and inappropriate use persist. • Evidence in Switzerland on the economic burden is scarce (mostly health-care costs and DALYs). • Developme
Slide 97: SP4: Productivity changes in diseases affected by AMR
SP4: Productivity changes in diseases affected by AMR Socioeconomic burden Productivity impairment Valuing lost/gained Health Burden productive time ▪ Identify disease ▪ Link health outcomes ▪ Translate changes in incidence to productivity (e.g. productivity to ▪ Health outcomes paid work) monetary
Slide 98: SP4: Cost savings from using DrugAlert
SP4: Cost savings from using DrugAlert (with SP1, USB) Estimated cost savings in work-hours (tool use hours) due to using DrugAlert: TOTAL SAVINGS TOTAL TIME SAVED SAVINGS per 100 patients per 100 patients AVGE SAVINGS/ SAVINGS/PATIENT- per 100 patients EQUIVALENT IN PATIENT (CHF) DAY (CHF) HOSPITAL
Slide 99: SP4: Earlier appropriate antibiotic therapy and mortality meta-analysis
SP4: Association between earlier appropriate antibiotic therapy and mortality in hospitalised bloodstream infection patients: meta-analysis Unpublished results: to be available post peer-review 99
Slide 100: SP4: Cost-effectiveness of strategies reducing time to appropriate therapy
SP4: Cost-effectiveness of strategies that reduce time to appropriate antibiotic therapy in hospitalised BSI patients Earlier: more effective Earlier: less effective and more costly and more costly Earlier: more effective and less costly Earlier: less effective and less costly 10 0
Slide 101: SP4: Health economics & HTA
SP4: Health economics & HTA Sub-project lead: European Center of Pharmaceutical Medicine, WifOR team: University of Basel Ms. Jennifer Branner Dr. Mark Lambiris Dr. Platon Peristeris Dr. Judith Lupatsch Dr. Jasper Ubels Mr. Christian Fischer Mr. Youssef Akladios Ms. Christina Thomas Prof. Matthias S
Slide 102: Morning reflections & afternoon highlights
12:10-12:15 Morning reflections & afternoon highlights Saara Malkamäki, University of Basel
Slide 103: Program
Program Time (CET) Content Speaker 13:15-14:45 Workshops: SPEARHEAD and Beyond Andrea Studer, USB, Cornelia Schneider, USB, Christoph Meier, • Real time monitoring for AMR USB, Lina Aerts, UKBB, Julia Bielicki, UKBB, Daniele Malpetti, SUPSI • Machine Learning for Optimised Antibiotic Use IDSIA, Alex
Slide 104: Workshops: SPEARHEAD and Beyond
13:15-14:45 Workshops: SPEARHEAD and Beyond Seminar Room 1 Real-time monitoring for AMR Andrea Studer, Cornelia How can we optimize inappropriate Schneider, Christoph Meier, antibiotic use? USB Seminar Room 2 Machine Learning for Optimised Lina Aerts, Julia Bielicki, Antibiotic Use UKBB, Daniele Mal
Slide 105: Keynote: Countering antimicrobial resistance (AMR) in a changing global health landscape
15:20-15:45 Keynote: Countering antimicrobial resistance (AMR) in a changing global health landscape: A smart, cost-effective approach Peter Beyer, Global Antibiotic Research and Development Partnership (GARDP)
Slide 106: Optimizing the product development partnership model for antibiotic resistance
Optimizing the product development partnership model for antibiotic resistance Peter Beyer Deputy Executive Director, GARDP 17 November 2025
Slide 107: GARDP: A Swiss Foundation with global reach
GARDP: A Swiss Foundation with global reach GARDP created by WHO GARDP established as a GARDP is a not-for-profit organization and the Drugs for Neglected Swiss foundation (GARDP with an annual budget of ~32MN CHF Disease initiative (DNDi) Foundation) and ~90 staff worldwide 2016 2018 TODAY
Slide 108: Bringing into focus what's most important in the antibiotic pipeline
Bringing into focus what’s most important in the antibiotic pipeline Quality over quantity Antibiotics that will make the most significant public health impact Balancing priorities Priority pathogens AND disease burden Longer-term and near-term solutions Innovative antibiotics & optimizing current t
Slide 109: GARDP is refining its disease area strategy
GARDP is refining its disease area strategy for future portfolio development HIGH-BURDEN PRIORITY DISEASES & INFECTIONS • Continued focus on innovative antibacterials • Balance between bacterial disease burden & AMR (e.g. optimizing and enabling access to current therapeutic GARDP tools v. developin
Slide 110: GARDP's expanding portfolio
CRE: Carbapenem-resistant Enterobacterales CRAB: Carbapenem-resistant Acinetobacter baumannii CRPA: Carbapenem-resistant Pseudomonas aeruginosa GARDP’s expanding portfolio PP: Priority pathogens ESBL: Extended-spectrum beta-lactamases producing Enterobacterales CR: Carbapenem-resistant SERIOUS BACTE
Slide 111: GARDP's starting point: license and collaboration agreements
GARDP’s starting point: license and collaboration agreements • GARDP = financial and scientific engagement + business development • A flexible role in R&D: • project driver/sponsor OR • shared leadership role (‘co-development model’) OR • supporting role only • For innovative antibiotics: License ag
Slide 112: GARDP portfolio overview
GARDP portfolio overview • Driven by disease area strategy • Mix of innovative antibiotics and optimizing current therapeutic tools • Six in-licensing agreements with partners SERIOUS BACTERIAL INFECTIONS 1. Cefiderocol (Shionogi) 2. BWC0977 IV (Bugworks) 3. BWC0977 oral (Bugworks) 4. Apramycin (Juv
Slide 113: Cefiderocol drug access project
Cefiderocol drug access project Appropriate access in up to 135 countries Collaboration agreement Manufacturing sublicense License & agreement technology transfer agreement Sublicense Supply agreement T.B.D . Commercial & distributor sublicense(s)
Slide 114: WW II poster in Louisiana
WW II poster in Louisiana, USA by the State Board of Health, and City Health Department.
Slide 115: Development of resistance in N. gonorrhoeae
Development of resistance in N. gonorrhoeae Year of reported resistance 1997 Azithromycin 2011 Over the past 80 1944 1990 Ceftriaxone years, the Neisseria Sulphonamides Ciprofloxacin gonorrhoeae 1986 2002 bacterium has 1967 Tetracycline Cefixime 1946 developed defenses Penicillin Spectinomycin again
Slide 116: Zoliflodacin drug development project
Zoliflodacin drug development project ▪ Investigational oral first-in-class antibiotic being developed for the treatment of uncomplicated gonorrhoea infection by GARDP & Innoviva Specialty Therapeutics ▪ GARDP enrolled nearly 1000 patients in 16 sites across 5 countries ▪ New Drug Application under
Slide 117: Global observational study of neonatal sepsis
Global observational study of neonatal sepsis In 2020, GARDP and its partners completed enrolment for one of the world’s largest neonatal sepsis observational studies to inform the development of Study sites antibiotic treatments and regimens for neonatal sepsis. More than 3,200 newborns recruited i
Slide 118: Clinical Development – NeoSep1 clinical trial
Clinical Development – NeoSep1 clinical trial Part 2 8 regimens to be tested: • 3 new combinations: • fosfomycin + amikacin • fosfomycin + flomoxef • flomoxef + amikacin • 5 additional regimens: • WHO-recommended and/or commonly used regimens To take place in at least 15 sites in 9 countries: Ghana
Slide 119: Clinical Development – NeoSep1 clinical trial
Clinical Development – NeoSep1 clinical trial Expected outcomes • New treatment options: The trial may identify one new regimen (or more) to treat neonatal Given the number of different sepsis options, choosing one of the best treatments out of the • Ranking of treatment options: multiple available
Slide 120: GARDP's strategy 2027-2031
GARDP’s strategy 2027-2031: Adapting to the changing global health landscape
Slide 121: GARDP's strategy 2027-2031
GARDP’s strategy 2027-2031 • GARDP is preparing an updated strategy for its next strategic phase, including: • Updated disease area strategy • Expanded portfolio • Strong framework for defining our role in product development and access • Evolved theory of change to understand and evaluate impact •
Slide 122: Seeking your input
Seeking your input • How can GARDP contribute to your efforts to counter AMR? What do you need from us? What would you like to see in GARDP’s new strategy?
Slide 123: Thank you
R Federal Ministry of Research, Technology and Space PY Ministry of Foreign Affairs With funding from the fe | fetes for Economic Cooperation and Development KFW ehrough Schweizerische Eidgenossenschaft Confederation suisse Confederazione Svizzera Contederaziun svizra BOR Ministry of Health, Welfare
Slide 124: Closing remarks
15:45-16:00 Closing remarks Julia Bielicki, University Children's Hospital Basel (UKBB), Saara Malkamäki, University of Basel, Christoph Nabholz, Swiss Re
Slide 125: Networking & Apéro
16:00-18:00 Networking & Apéro Funded by Innosuisse